SuperworthArvinas EPS ARVN
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- $0.16
- Latest quarter, Q2 FY26
- $2.58
- Fiscal year 2025
- −$1.22
Arvinas' earnings per share was $0.16 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $2.58.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.22 | n/a |
| FY2024 | −$2.77 | n/a |
| FY2023 | −$6.50 | n/a |
| FY2022 | −$5.31 | n/a |
| FY2021 | −$3.82 | n/a |
| FY2020 | −$2.99 | n/a |
| FY2019 | −$2.11 | n/a |
| FY2018 | −$114.72 | n/a |
| FY2017 | −$15.08 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $2.58 | n/a | $0.16 | |
| Q1 FY26 | −$0.90 | −179% | −$3.26 | |
| Q4 FY25 | −$1.04 | n/a | −$1.22 | |
| Q3 FY25 | −$0.48 | n/a | −$0.81 | |
| Q2 FY25 | −$0.84 | n/a | −$1.01 | |
| Q1 FY25 | $1.14 | n/a | −$0.66 | |
| Q4 FY24 | −$0.63 | n/a | −$2.77 | |
| Q3 FY24 | −$0.68 | n/a | −$4.67 | |
| Q2 FY24 | −$0.49 | n/a | −$5.17 | |
| Q1 FY24 | −$0.97 | n/a | −$5.93 | |
| Q4 FY23 | −$2.53 | n/a | −$6.50 | |
| Q3 FY23 | −$1.18 | n/a | −$5.52 |
Against its peers
Companies in Drug Manufacturers - General nearest Arvinas' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| PCRXPacira BioSciences | $0.35 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Arvinas
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.